



# Human Immunodeficiency Virus Type 1 (HIV-1) GenoSure Archive

## LABORATORIES

Patient: [REDACTED]  
DOB: [REDACTED] Age: 79 Sex: M  
Patient Identifiers: [REDACTED] [REDACTED]  
Visit Number (FIN): [REDACTED]

Client: [REDACTED]  
Physician: [REDACTED]

ARUP Test Code: 3002503  
Collection Date: 05/18/2023  
Received in lab: 05/19/2023  
Completion Date: 06/13/2023

## TEST INFORMATION

Test performed at Labcorp Monogram Biosciences, 345 Oyster Point Blvd., South San Francisco, CA 94080

## PATIENT REPORT

Patient's results continue on following page(s).



Patient: [REDACTED]  
ARUP Accession: 23-138-123391

Weidong Huang, MD, Medical Director  
345 Oyster Point Blvd  
South San Francisco, CA 94080 - Tel: (800) 777-0177

Client: [REDACTED] Project: [REDACTED]  
Phone: (800) 242-2787 Fax: (801) 584-5132

Patient Name [REDACTED]	DOB [REDACTED]	Patient ID/Medical Record # [REDACTED]	Gender M	Monogram Accession # [REDACTED]
Date Collected 18-MAY-2023 15:43	Date Received 20-MAY-2023 12:35 PT	Date Reported 13-JUN-2023 11:11 PT	Mode F,L,W	Report Status FINAL
Referring Physician [REDACTED]	Reference Lab ID/Order # 23-138-123391			
Comments HIV-1 Subtype: <b>B</b>				

	Generic Name	Brand Name	Assessment	Drug Resistance Associated Mutations Detected	Comments
NRTI	Abacavir	Ziagen	Resistant	M41M/L, D67D/N, L74L/V, V75V/A, M184M/V, T215T/N/S/Y	
	Didanosine	Videx	Resistant	M41M/L, D67D/N, L74L/V, V75V/A, M184M/V, T215T/N/S/Y	
	Emtricitabine	Emtriva	Resistant	M41M/L, D67D/N, M184M/V, T215T/N/S/Y	
	Lamivudine	EpiVir	Resistant	M41M/L, D67D/N, M184M/V, T215T/N/S/Y	
	Stavudine	Zerit	Resistant	M41M/L, D67D/N, V75V/A, T215T/N/S/Y	1
	Tenofovir	Virad	Resistance Possible	M41M/L, D67D/N, V75V/A, T215T/N/S/Y	2
	Zidovudine	Retrovir	Resistant	M41M/L, D67D/N, V75V/A, T215T/N/S/Y	2
NNRTI	Doravirine	Pifeltro	Sensitive	None	
	Efavirenz	Sustiva	Sensitive	None	
	Etravirine	Intelence	Sensitive	None	
	Nevirapine	Viramune	Sensitive	None	
	Rilpivirine	Eduvant	Sensitive	None	
INI	Bictegravir	Bictegravir	Sensitive	None	
	Dolutegravir	Tivicay	Sensitive	None	
	Elvitegravir	Vitekta	Sensitive	None	
	Raltegravir	Isentress	Sensitive	None	
PI	Atazanavir	Reyataz / r†	Resistant	L10L/I, E35E/D, M36I, M46M/I, I54I/V, V82V/A/I/T, N88N/S	
	Darunavir	Prezista / r†	Sensitive	L10L/I, M46M/I, V82V/A/I/T	3
	Fosamprenavir	Lexiva / r†	Sensitive	L10L/I, E35E/D, M46M/I, I54I/V, V82V/A/I/T	3
	Indinavir	Crixivan / r†	Resistant	L10L/I, M36I, M46M/I, I54I/V, A71A/T, V82V/A/I/T, N88N/S	
	Lopinavir	Kaletra †	Resistant	L10L/I, M46M/I, I54I/V, A71A/T, V82V/A/I/T	
	Nelfinavir	Viracept	Resistant	L10L/I, E35E/D, M36I, M46M/I, I54I/V, A71A/T, V82V/A/I/T, N88N/S	
	Ritonavir	Norvir	Resistant	L10L/I, E35E/D, I54I/V, A71A/T, V82V/A/I/T	
	Saquinavir	Invirase / r†	Resistant	L10L/I, E35E/D, I54I/V, A71A/T, N88N/S	
	Tipranavir	Aptivus / r†	Resistant	I13I/V, E35E/D, M36I, I54I/V, V82V/A/I/T	



Weidong Huang, MD, Medical Director  
345 Oyster Point Blvd  
South San Francisco, CA 94080 - Tel: (800) 777-0177

Client: [REDACTED]  
Phone: (800) 242-2787

Project: [REDACTED]  
Fax: (801) 584-5132

Patient Name	DOB	Patient ID/Medical Record #	Gender	Monogram Accession #
[REDACTED]	[REDACTED]	[REDACTED]	M	[REDACTED]
Date Collected	Date Received	Date Reported	Mode	Report Status
18-MAY-2023 15:43	20-MAY-2023 12:35 PT	13-JUN-2023 11:11 PT	F,L,W	FINAL

\* Assessment of drug susceptibility is based upon detected mutations and interpreted using an advanced proprietary algorithm (version 18).  
 † Interpretation algorithms for ritonavir-boosted protease inhibitors appropriate for the following dosages: AMP/r 600mg/100mg BID; ATV/r 300mg/100mg QD; IDV/r 800mg/200mg BID; LPV/r 400mg/100mg BID; SQV/r 1000mg/100mg BID; TPV/r 500mg/200mg BID; and DRV/r 600mg/100mg BID.  
 \* **Mixtures** are indicated by amino acids separated by a slash. Deletions in the amino acid sequence are indicated by a ^ symbol.

M	D	L	V	M	T			
41	57	74	75	184	215			
NRTI	D	L	V	M	T			
M	N	V	A	V	N			
L					S			
					Y			
L	I	E	M	M	I	A	V	N
10	13	35	36	46	54	71	82	88
PI	I	E	I	M	I	A	V	N
L	V	D		I	V	T	A	S
							I	
							T	

**Summary of Mutations Observed**

**RT** K20K/R, V35V/A/I/T, M41M/L, D67D/N, L74L/V, V75V/A, Q102K, Y115Y/H, K122K/E, C162S, T165T/I, K166K/R, M184M/V, G196G/E, R211R/K, T215T/N/S/Y, E248E/D, G262G/E, T286A, V293I, E308E/K, R356R/K, M357M/I/T, A360A/T, A371A/V, A376T, K390R, E399D, A400A/I/T/V  
**IN** H51H/Q, L101L/I, V113I, E157E/K, E198D, Q216H, V234L, S283S/G  
**PR** L10L/I, I13I/V, E35E/D, M36I, N37N/D, R41R/K, M46M/I, I54I/V, L63L/F/P/S, A71A/T, V82V/A/I/T, N88N/S

**Genotype Comments (clinical significance may vary)**

- Assessment for this drug was derived considering the sensitizing effect of mutation M184V.
- Assessment for this drug was derived considering the sensitizing effect of mutations L74V and M184V.
- Assessment for this drug was derived considering the sensitizing effect of mutation N88S.

**For more information on interpreting this report, please visit [monogrambio.labcorp.com](http://monogrambio.labcorp.com) or call Customer Service at 800-777-0177 between the hours of 6:30am to 5:00pm PT Monday through Friday.**

GenoSure Archive is a DNA sequencing assay that uses next-generation sequencing to analyze the protease (amino acids 1-99), reverse transcriptase (amino acids 1-400) and integrase (amino acids 1-288) coding regions derived from HIV-1 cell associated DNA. Subtype is determined using the protease and reverse transcriptase sequence information. This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration. Monogram Biosciences, Inc. is a subsidiary of Laboratory Corporation of America Holdings, using the brand Labcorp. The results should not be used as the sole criteria for patient management. This document contains private and confidential health information protected by state and federal law. If you have received this document in error, please call 800-777-0177.

